Lymphocyte activation gene-3 (LAG-3) 是一种免疫检查点蛋白,属于免疫球蛋白超家族。LAG-3 主要表达于活化的 T 细胞、NK 细胞、B 细胞和浆细胞样树突状细胞上。LAG-3 对主要组织相容性复合体 II 类分子具有高亲和力,也可与纤维蛋白原样蛋白 1 (FGL1) 结合。LAG-3 与其配体结合后会抑制 T 细胞的活化和增殖,从而调节免疫反应。在肿瘤微环境中,LAG-3 会过度表达,这有助于肿瘤细胞逃避免疫监视。LAG-3 被认为是癌症免疫治疗的重要靶点。除了在肿瘤免疫中的作用外,LAG-3 也参与一些自身免疫性疾病和感染性疾病的发病机制[1][2][3]。
Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint protein that belongs to the immunoglobulin superfamily. LAG-3 is mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells. LAG-3 has a high affinity for MHC class II molecules and can also bind to FGL1. Binding of LAG-3 to its ligands leads to the inhibition of T cell activation and proliferation, thereby regulating the immune response. In the tumor microenvironment, overexpression of LAG-3 is often observed, which helps tumor cells escape immune surveillance. LAG-3 is considered as an important target for cancer immunotherapy. In addition to its role in tumor immunity, LAG-3 is also involved in the pathogenesis of some autoimmune diseases and infectious diseases[1][2][3].
Anti-Mouse FGL-1 Antibody (177R4) 是一种抗小鼠 FGL-1 IgG2a 单克隆抗体,可通过阻断 FGL1 增强抗肿瘤免疫效果并增加 CD8+ T 细胞浸润,可用于肺癌和膀胱癌等癌症的研究。
Z3071585108 是一种靶向 LAG-3 D1 结构域的小分子结合剂,其在 MST-TRIC 通道和光谱位移检测中测得的 Kd 值分别为 59.2 和 56.1 μM,并以 42.9 μM 的 EC₅₀ 部分抑制 LAG-3 与 MHCII 的结合,可用于研究靶向 LAG-3 的小分子免疫疗法。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号